Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

NCT01825148

Type 1 Diabetes

COMPLETED

The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

NCT00747968

Type 2 Diabetes

COMPLETED PHASE2/PHASE3

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338

Healthy

COMPLETED PHASE3

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

NCT02584582

Type 1 Diabetes

UNKNOWN PHASE2/PHASE3

Effect of Gelofusine on GLP1-receptor Imaging

NCT02541734

Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Reliable imaging biomarkers for non-invasive characterisation of beta-cell mass (BCM) are needed to aid understanding regarding the relationship between beta-cell mass and function during the course of type 2 diabetes (T2D). This study will provide critical information necessary to validate the applicability of exendin-based imaging techniques in patients with T2D. The characterization of beta-cells is currently limited to pancreatic specimens available at autopsy, as in vivo pancreatic biopsy is associated with complications unacceptable in clinical studies. To date, only measurements of circulating C-peptide and insulin levels can be obtained, but these measures do not reflect beta-cell mass, only total beta-cell function. Reliable imaging biomarkers for non-invasive characterisation of beta cell mass are therefore needed. These biomarkers could also be used to validate novel therapeutic strategies aimed to increase or preserve BCM or identify whether patients are eligible for a certain therapeutic strategy (e.g. when certain amount of beta-cells is required). One can also think of identifying early responders to therapies, to avoid unnecessary drug use and the accompanying costs.

The objective of this study is to determine the specificity of Exendin-4 during the course of T2D and to examine the role of glycemic control on the correlation between pancreatic Exendin-4 uptake, BCM and GLP-1R expression in patients with T2D undergoing (partial) pancreatectomy. This will allow examination of the role of glycemic control on exendin uptake in humans, but also implementation of clinical guidelines for the interpretation of clinical exendin-based scans in patients with T2D to avoid false interpretation of the scans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

111In-exendin-DTPA

Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography

Group Type EXPERIMENTAL

111In-DTPA-exendin-4

Intervention Type DRUG

Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography

exendin-IRDye800CW

Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy

Group Type EXPERIMENTAL

IRDye800CW-exendin-4

Intervention Type DRUG

Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

111In-DTPA-exendin-4

Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography

Intervention Type DRUG

IRDye800CW-exendin-4

Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled for partial or complete pancreatectomy at Radboudumc

Exclusion Criteria

* Previous treatment with synthetic exendin or dipeptidyl-peptidase IV inhibitors within the past 3 months
* Breast feeding
* Pregnancy or the wist to become pregnant within 6 months
* Creatinine clearance below 40ml/min
* Liver disease defined as aspartate aminotransferase of alanine aminotransferase level of more than three times the upper limit of normal range

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No